The range of symptoms included, along with the age of onset and progression, is so diverse that it makes diagnosing and therapy mitochondrial diseases a cumbersome task. The tissues that suffer the most damage include the heart, skeletal muscles, brain, and retina because those organs have the highest oxidative metabolism. Protheragen, as a leading preclinical research service provider focused on developing and understanding mitochondrial diseases, puts forth its unwavering commitment to solving problems through custom cell therapy development services for the diseases.
Cell Therapies in Mitochondrial Disease
The advancement of research has paved the way for promising cell-based strategies in the treatment of diverse mitochondrial disease.
| Method |
Disease |
| Erythrocyte-encapsulated thymidine phosphorylase |
Mitochondrial NeuroGastroIntestinal Encephalomyopathy (MNGIE) |
| Allogenic HSCT |
Mitochondrial NeuroGastroIntestinal Encephalomyopathy (MNGIE) |
| Liver transplantation |
Ethylmalonic encephalopathy (EE) |
Our Services
The scope of our cell therapy development services encompasses a diverse range of activities aimed at expediting the translation of promising therapies into efficacious treatments for mitochondrial diseases.
Cell Line
Development
Specialize in the generation and optimization of cell lines for mitochondrial disease research. Our team utilizes advanced techniques to develop disease-specific cell lines that accurately mimic the physiological conditions of the target organ or tissue affected by mitochondrial disease. These cell lines serve as valuable tools for preclinical studies and drug screening.
Cell-Based Assay
Development
Create and test cell-based assays for the evaluation of the effectiveness and safety of potential cell therapies for mitochondrial diseases. Our assays are directed toward evaluating key cellular functions that are impacted by the impairment of the mitochondrion, including, but not limited to, energy production, oxidative stress, and mitochondrial dynamics.
Cell Therapy
Manufacturing
Focus on the development and improvement of the processes for the manufacture of cell therapies with an emphasis on assuring scalability and reproducibility within defined quality control parameters. We adapt the manufacturing protocols to regulatory standards, enabling the effective progression of cell therapies from the laboratory to the preclinical stage.
Preclinical Efficacy and
Safety Studies
In-depth preclinical trials study the effectiveness and safety of cell therapy for mitochondrial diseases in appropriate animal models. We evaluate the therapy results meticulously, which include functional improvements, tissue regeneration, and immune response modulation. Such studies furnish essential information for regulatory submissions.
Our Advantages
Professional Team
Advanced Technology
Comprehensive Services
Reliable Data and Results
At Protheragen, we place great effort on progressing cell therapy development for using it in cases of mitochondrial diseases. Our wide array of services, combined with our knowledge in researching mitochondrial diseases, enables us to proficiently assist our clients in developing new and effective therapeutics. Contact us today so we can discuss how our prowess in cell therapy development can help you in fighting mitochondrial diseases.
